FlowSense was acquired by Baxter in September 2013.
FlowSense has developed an advanced fluid monitoring system for accurate, continuous, real-time monitoring of urine output.
FlowSense’s URINFO 2000 is based on its patented optical sensing technology and unique disposable. Continuous, real-time data is collected automatically and accessible to clinicians at any time. The product consists of two components:
URINFO is available in two configurations: stand-alone system at the patients’ bedside and integrated with clinical information systems.
Stage: Public company (Tel Aviv Stock Exchange)
In the media: Baxter acquires FlowSense
Measurement of urine output is a key indicator of a patient’s fluid balance and renal condition, particularly in the critical care setting. Acute kidney injury occurs in approximately 5% of all hospitalized patients and in 30% of critical care patients, resulting in higher costs of care and higher mortality rates.
Today, urine output is measured with mechanical urine meters, which are labor intensive, based on manual volume readings, and do not provide urine output data necessary for timely detection and treatment of kidney injury. FlowSense has developed an advanced fluid monitoring system for accurate, continuous, real-time monitoring of urine output.
Wireless, wearable vital sign monitoring system
Cryotherapy for superficial bladder cancer
Endoscopic ultrasound fine needle biopsy
Portable, automatic system for peritoneal dialysis
Device for treating ischemic stroke
Anastomotic closure device for laparoscopic bowel resection